Lexaria Biosciences
NASDAQ · LEXX

Lexaria Biosciences

Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and many more patents pending worldwide. Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery.

Sign in to join this pass
Create a free account to join, then verify your holdings.
Increases bio-absorption many-fold
Reduces time of onsest from 1-2 hours to minutes
Delivers drugs more effectively across the blood brain barrier
Improves tolerability
Increases bio-absorption many-fold
Reduces time of onsest from 1-2 hours to minutes
Delivers drugs more effectively across the blood brain barrier
Improves tolerability
Increases bio-absorption many-fold
Reduces time of onsest from 1-2 hours to minutes
Delivers drugs more effectively across the blood brain barrier
Improves tolerability
Increases bio-absorption many-fold
Reduces time of onsest from 1-2 hours to minutes
Delivers drugs more effectively across the blood brain barrier
Improves tolerability
Richard Christopher

Richard Christopher

CEO

LinkedIn
John Docherty

John Docherty

President and Chief Scientific Officer

LinkedIn
Michael Shankman, CPA

Michael Shankman, CPA

CFO

LinkedIn